Atai Beckley’s $3.8 Billion Lilly Deal Splits Wall Street as Milestone Payments Fuel a Two-Tiered Bet
Published on 07/22/2026 at 02:30 | Redaktion boerse-global.de
The acquisition of Atai Beckley by Eli Lilly has created an unusual schism among analysts, with most downgrading the stock to near the deal price while one firm keeps a target more than double the maximum possible payout — a divergence that underscores just how much uncertainty still surrounds the transaction’s contingent value rights.
Lilly agreed on July 16, 2026, to pay $6.75 per share in cash plus up to $2.50 per share in Contingent Value Rights, valuing the total deal at as much as $3.8 billion. The boards of both companies have approved the transaction, which is expected to close in the third quarter of 2026. The immediate cash component accounts for roughly $2.8 billion of that sum.
H.C. Wainwright moved its rating from Buy to Neutral and slashed its price target from $25 to $7.50, while Jefferies downgraded from Buy to Hold with the same $7.50 target. Both firms argued that with the deal locked in, there is little room for further upside beyond the offer terms.
Oppenheimer, however, held firm at Outperform with a $16 price target — a figure that sits well above even the maximum combined value of the cash and CVR components. The disparity suggests that Oppenheimer either sees a meaningful chance the deal structure changes or assigns significant standalone value to Atai Beckley’s pipeline that could survive outside the transaction.
Should investors sell immediately? Or is it worth buying Atai Beckley?
The CVR structure ties the extra payments to specific regulatory milestones. Shareholders receive $1.00 per share if VLS-01 enters a Phase 3 trial by the fourth anniversary of the deal’s close. Another $0.50 per share is triggered if BPL-003 receives FDA approval and is rescheduled by the Drug Enforcement Administration by the fifth anniversary. A final $1.00 per share depends on VLS-01 achieving the same regulatory milestones by the seventh anniversary.
BPL-003, an intranasal 5-MeO-DMT treatment for treatment-resistant depression, already holds FDA Breakthrough Therapy designation and is in Phase 3. VLS-01, a buccal DMT formulation, is currently in Phase 2b. The pipeline also includes EMP-01, an MDMA-based candidate for social anxiety disorder.
The deal arrives amid a supportive political environment for psychedelic research. On July 13, the Department of Health and Human Services and the Department of Veterans Affairs signed a five-year agreement to jointly study psychedelic therapies. The same day, the FDA released final guidance for clinical trials involving these substances, requiring two trained monitors per session and a physician within 15 minutes’ reach.
For Lilly, the acquisition marks its eleventh drugmaker purchase this year — roughly one transaction every eight to nine days. The broader sector has seen additional consolidation, with AbbVie acquiring Gilgamesh for up to $1.2 billion and Otsuka securing Transcend for a similar amount.
The market reaction among peers has been mixed. Compass Pathways, despite the positive signal from Lilly’s entry into the space, fell more than 5% to a five-day low. That decline came even as Evercore ISI upgraded Compass to Outperform and raised its price target from $8 to $21. The global psychedelic drug market is estimated at roughly $4.6 billion in 2026 and is projected to grow to about $8.8 billion by 2031.
Atai Beckley at a turning point? This analysis reveals what investors need to know now.
Atai Beckley shares currently trade at around €6.20, roughly 21% below the 52-week high of €7.85 set on July 16 — the day the deal was announced. The stock has surged more than 75% over the past 30 days, pushing the Relative Strength Index to 73.8, well into overbought territory. The secondary article reports a slightly higher RSI of 75.7 and a 79.38% 30-day gain, but both readings point to the same conclusion: the easy money has been made.
With the acquisition price largely baked in, the remaining debate centers on how much faith the market places in the CVR milestones — and whether Oppenheimer’s outlier view reflects a genuine contrarian bet or simply a slow adjustment to the new reality. For most investors, the stock’s trajectory from here will track the closing process and the formal completion announcement expected in the third quarter.
Ad
Atai Beckley Stock: New Analysis - 22 July
Fresh Atai Beckley information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
